Doris Hoeflmayer

528 total citations
10 papers, 115 citations indexed

About

Doris Hoeflmayer is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Doris Hoeflmayer has authored 10 papers receiving a total of 115 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Doris Hoeflmayer's work include PI3K/AKT/mTOR signaling in cancer (4 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Sphingolipid Metabolism and Signaling (2 papers). Doris Hoeflmayer is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (4 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Sphingolipid Metabolism and Signaling (2 papers). Doris Hoeflmayer collaborates with scholars based in Austria, Germany and United States. Doris Hoeflmayer's co-authors include Volker Wacheck, Thorsten Fuereder, Sabine Strommer, Richard Crevenna, Daniel Cejka, Matthias Preusser, Stefan Koehrer, Markus Müller, Oliver Langer and Thomas Wanek and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Cancer Letters.

In The Last Decade

Doris Hoeflmayer

10 papers receiving 113 citations

Peers

Doris Hoeflmayer

MB

PRM

ONCOL

CR

PFM

Desam Roda United Kingdom

Bethany Kaplan United States

Haitao Ma China

Michel Velez United States

Cody Weimholt United States

Supriya Jain United States

Mai Q. Nguyen United States

Andrea Lindgren Sweden

Rajni Sonavane United States

Desam Roda United Kingdom

Doris Hoeflmayer

81 ×1.3

MB

29 ×0.8

PRM

66 ×1.9

ONCOL

44 ×1.5

CR

16 ×0.8

PFM

Citations per year, relative to Doris Hoeflmayer Doris Hoeflmayer (= 1×) peers Desam Roda

Countries citing papers authored by Doris Hoeflmayer

Since Specialization

Citations

This map shows the geographic impact of Doris Hoeflmayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris Hoeflmayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris Hoeflmayer more than expected).

Fields of papers citing papers by Doris Hoeflmayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doris Hoeflmayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris Hoeflmayer. The network helps show where Doris Hoeflmayer may publish in the future.

Co-authorship network of co-authors of Doris Hoeflmayer

This figure shows the co-authorship network connecting the top 25 collaborators of Doris Hoeflmayer. A scholar is included among the top collaborators of Doris Hoeflmayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doris Hoeflmayer. Doris Hoeflmayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Lennartz, Maximilian, Florian Viehweger, David Dum, et al.. (2023). Abstract 5457: Prevalence of “low” HER2 expression is frequent in breast cancer but also in cancers of other origin: A tissue microarray study on 131 tumor types. Cancer Research. 83(7_Supplement). 5457–5457. 1 indexed citations

2.

Uhlig, Ria, Sören Weidemann, Doris Hoeflmayer, et al.. (2021). Carboxypeptidase A1 (CPA1) immunohistochemistry is highly sensitive and specific for acinar cell carcinoma (ACC) of the pancreas. Pathology. 53. S43–S43. 2 indexed citations

3.

Kluth, Martina, Christina Möller‐Koop, Eike Burandt, et al.. (2019). 5q21 deletion is often heterogeneous in prostate cancer. Genes Chromosomes and Cancer. 58(8). 509–515. 1 indexed citations

4.

Fuereder, Thorsten, Judith Stift, Irene Kuehrer, et al.. (2014). Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression. European Journal of Clinical Investigation. 44(10). 958–964. 8 indexed citations

5.

Fuereder, Thorsten, Thomas Wanek, Doris Hoeflmayer, et al.. (2011). Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake. Clinical Cancer Research. 17(16). 5322–5332. 31 indexed citations

6.

Cejka, Daniel, Ying Liu, Matthias Preusser, et al.. (2010). Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biology & Therapy. 9(11). 919–927. 8 indexed citations

7.

Fuereder, Thorsten, Doris Hoeflmayer, Matthias Preusser, et al.. (2010). mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Letters. 296(2). 249–256. 36 indexed citations

8.

Fuereder, Thorsten, Doris Hoeflmayer, Sabine Strommer, et al.. (2010). Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anti-Cancer Drugs. 22(3). 245–252. 22 indexed citations

9.

Füreder, Thorsten, Thomas Wanek, Doris Hoeflmayer, et al.. (2010). BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo. BMC Pharmacology. 10(S1). 5 indexed citations

10.

Füreder, Thorsten, et al.. (2008). Targeting sphingosine kinase 1 with LNA oligonucleotides in gastric cancer. BMC Pharmacology. 8(S1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact